Elite Journal of Haematology. Volume 2 issue 5(2024), Pp. 126-137
https://epjournals.com/journals/EJH

Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Howell-Jolly bodies (HJBs), cytoplasmic remnants of DNA in erythrocytes, have garnered attention as potential indicators of disease progression in HIV patients. This review explores the intricate relationship between the presence of HJBs and the progression of HIV, elucidating morphological features and underlying mechanisms linking their occurrence to disease severity. The morphological features of HJBs, observed as small, round, basophilic inclusions within erythrocytes, signify abnormalities in erythropoiesis and splenic function, providing valuable insights into HIV-related complications. Moreover, elevated viral loads and decreased CD4+ T-cell counts are often concomitant with an abundance of HJBs, suggesting their potential as prognostic markers and therapeutic targets. Mechanistically, dysregulated erythropoiesis, increased red cell turnover, and impaired splenic function in HIV-infected individuals contribute to the formation of HJBs, highlighting the intricate interplay between HIV pathogenesis and hematological abnormalities. Detection of HJBs in HIV patients holds clinical significance, offering a non-invasive means of assessing disease progression and identifying individuals at higher risk of developing complications. Integrating HJB assessment into routine hematological evaluations may facilitate early intervention and tailored therapeutic approaches, ultimately improving patient outcomes.

Keywords*: Howell-Jolly bodies, HIV, morphology, disease progression, erythrocytes, spleen, opportunistic infections*

Citation: Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology, 2024; 2(5):* 126-137

Introduction

Howell-Jolly bodies (HJBs), initially recognized as remnants of erythropoiesis in individuals with functional asplenia or splenic dysfunction, have emerged as intriguing markers of hematological abnormalities in various clinical contexts. In the realm of human immunodeficiency virus (HIV) infection, the presence of HJBs has garnered significant interest as a potential indicator of disease progression and immune dysfunction. HIV, a global health challenge affecting millions worldwide, is characterized by progressive immune deterioration, leading to acquired immunodeficiency syndrome (AIDS) if left untreated. While antiretroviral therapy (ART) has revolutionized the management of HIV, there remains a need for reliable prognostic markers to guide therapeutic decisions and monitor disease progression. The morphology of HJBs, characterized by small, round, basophilic inclusions within erythrocytes, reflects underlying abnormalities in erythropoietic processes and splenic function. Under physiological conditions, the spleen plays a pivotal role in erythrocyte maturation and quality control, efficiently removing senescent or abnormal erythrocytes from circulation. However, in the setting of HIV infection, splenic architecture and function may be compromised, leading to impaired erythrocyte clearance and the accumulation of HJBs in peripheral blood smears. Consequently, the presence and abundance of HJBs serve as morphological indicators of splenic dysfunction and altered erythropoiesis, providing valuable insights into the hematological manifestations of HIV.[1-13]

The abundance of HJBs has been linked to specific virological and immunological parameters, such as elevated viral loads and decreased CD4+ T-cell counts, suggesting a potential role in predicting treatment outcomes and guiding therapeutic interventions. Understanding the underlying mechanisms driving HJB formation in HIV is crucial for elucidating their clinical significance and therapeutic implications. Dysregulated erythropoiesis, increased red cell turnover, and immune-mediated splenic dysfunction are key contributors to HJB formation in HIV-infected individuals, highlighting the complex interplay between viral pathogenesis and hematological abnormalities. The clinical implications of detecting HJBs in HIV patients extend beyond mere diagnostic curiosity, offering actionable insights into disease progression and prognosis. Integrating HJB assessment into routine hematological evaluations may facilitate risk stratification and early identification of individuals at higher risk of developing HIV-related complications. Moreover, monitoring changes in HJB abundance over time could serve as a dynamic marker of treatment response and disease trajectory, guiding therapeutic adjustments and optimizing clinical outcomes. Despite their potential clinical utility, several questions regarding the kinetics, stability, and predictive value of HJBs in HIV management remain unanswered, necessitating further investigation.[14-23]

This review aims to comprehensively explore the role of HJBs in HIV, from their morphological features to their clinical implications and underlying pathophysiological mechanisms.

Morphological Features of Howell-Jolly Bodies

Citation: Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology, 2024; 2(5):* 126-137

The morphological features of Howell-Jolly bodies (HJBs) provide valuable insights into the underlying erythropoietic abnormalities and splenic dysfunction observed in HIV-infected individuals. HJBs are characterized as small, round, basophilic inclusions within erythrocytes, typically visible on peripheral blood smears stained with Wright-Giemsa or Romanowsky stains. These distinctive cytoplasmic remnants arise from the failure of the erythrocyte to expel its nucleus during maturation in the bone marrow, a process normally facilitated by the spleen's quality control mechanisms. In individuals with functional asplenia or compromised splenic function, such as those with HIV infection, the absence or dysfunction of the spleen impairs its ability to effectively clear senescent or abnormal erythrocytes from circulation. Consequently, erythrocytes containing residual nuclear material, manifested as HJBs, evade splenic filtration and persist in the peripheral blood. The presence of HJBs serves as a morphological hallmark of impaired erythropoiesis and splenic dysfunction, offering clinicians valuable diagnostic clues and insights into the pathophysiological processes at play in HIV-related hematological abnormalities.[24-35]

Under light microscopy, HJBs appear as discrete, uniformly staining bodies within erythrocytes, often exhibiting a characteristic blue-black hue against the pink background of the cytoplasm. The size of HJBs may vary but typically ranges from 1 to 3 micrometers in diameter, rendering them distinguishable from other cytoplasmic inclusions or artifacts. While HJBs are most commonly observed as single entities within individual erythrocytes, multiple HJBs may occasionally be present, reflecting a higher degree of erythropoietic perturbation and splenic dysfunction. In addition to their characteristic appearance on peripheral blood smears, the abundance of HJBs may vary depending on the severity of splenic dysfunction and the degree of erythropoietic stress in HIV-infected individuals. While low levels of HJBs may be observed in healthy individuals under certain physiological conditions, such as during periods of increased erythropoietic demand, their presence in excess or in association with other hematological abnormalities warrants further evaluation in the context of HIV infection. Quantitative assessment of HJBs, either manually or through automated image analysis techniques, may provide clinicians with valuable quantitative data to aid in risk stratification and prognostication for HIV-infected individuals.[36-40]

Association with Disease Progression

The association between Howell-Jolly bodies (HJBs) and disease progression in HIV is a topic of growing interest, offering valuable insights into the evolving landscape of hematological abnormalities and immune dysfunction in affected individuals. Numerous clinical studies have established a positive correlation between the presence of HJBs and advanced stages of HIV disease, including the development of AIDS-defining illnesses and opportunistic infections. The abundance of HJBs in peripheral blood smears has emerged as a potential morphological marker for assessing disease severity and predicting clinical outcomes in HIV-infected patients. In individuals with HIV, the presence of HJBs has been linked to various virological and immunological parameters indicative of disease progression. Elevated viral loads, reflecting increased viral replication and disease activity, are often observed in conjunction with a higher

prevalence of HJBs in peripheral blood smears. Moreover, decreased CD4+ T-cell counts, a hallmark of HIV-induced immunosuppression, are frequently associated with the presence of HJBs, suggesting a potential link between erythropoietic abnormalities and immune dysfunction in HIV-infected individuals.[41-51]

The association between HJBs and disease progression in HIV underscores the multifactorial nature of hematological abnormalities in affected individuals. Dysregulated erythropoiesis, characterized by increased red cell turnover and ineffective erythrocyte maturation, contributes to the accumulation of HJBs in circulation. Concurrently, HIV-induced immunosuppression leads to splenic atrophy and dysfunction, impairing the spleen's ability to efficiently clear abnormal erythrocytes, including those containing HJBs. The interplay between erythropoietic stress, immune dysfunction, and viral pathogenesis culminates in the progressive accumulation of HJBs and the associated hematological complications observed in advanced HIV disease. The clinical implications of detecting HJBs in HIV patients extend beyond mere prognostication, offering actionable insights into disease management and therapeutic decision-making. The presence of HJBs may serve as a morphological biomarker for identifying individuals at higher risk of developing HIV-related complications, prompting clinicians to initiate timely interventions and tailored therapeutic strategies. Moreover, monitoring changes in HJB abundance over time may provide clinicians with valuable prognostic information, guiding treatment adjustments and optimizing clinical outcomes for affected individuals.[40-41]

Mechanisms Underlying Howell-Jolly Body Formation

The formation of Howell-Jolly bodies (HJBs) in HIV is rooted in a complex interplay of dysregulated erythropoiesis, compromised splenic function, and immune-mediated abnormalities, shedding light on the intricate mechanisms underlying hematological abnormalities in affected individuals. Erythropoiesis, the process by which erythrocytes are produced in the bone marrow, is perturbed in HIV due to various factors, including direct viral effects, cytokine dysregulation, and nutritional deficiencies. As a result, erythrocyte maturation may be impaired, leading to the retention of residual nuclear material within circulating erythrocytes, manifested as HJBs. The spleen plays a crucial role in maintaining erythrocyte homeostasis by selectively removing aged, damaged, or abnormal erythrocytes from circulation. In individuals with HIV, splenic architecture and function may be compromised due to chronic immune activation, viral infiltration, and fibrotic changes, resulting in splenic atrophy and dysfunction. Consequently, the spleen's ability to effectively clear abnormal erythrocytes, including those containing HJBs, is impaired, leading to their accumulation in peripheral blood.[52-56]

Furthermore, HIV-induced immunosuppression exerts indirect effects on erythropoiesis and splenic function, further exacerbating the formation of HJBs.[57] Dysregulated cytokine production, particularly elevated levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), can disrupt erythropoietin production and impair

erythrocyte maturation in the bone marrow.[58] Additionally, immune-mediated destruction of erythrocytes, known as autoimmune hemolytic anemia, may occur in HIV-infected individuals, contributing to increased red cell turnover and the subsequent accumulation of HJBs. The accumulation of HJBs in peripheral blood serves as a morphological hallmark of splenic dysfunction and altered erythropoiesis in HIV-infected individuals, offering valuable insights into the pathophysiological mechanisms underlying hematological abnormalities in affected individuals. The presence and abundance of HJBs have been correlated with disease progression, opportunistic infections, and mortality in HIV, highlighting their clinical significance as potential prognostic markers and therapeutic targets. Understanding the mechanisms driving HJB formation in HIV is crucial for elucidating the pathogenesis of hematological complications and guiding targeted therapeutic interventions to optimize patient outcomes.

Clinical Implications and Therapeutic Considerations

The detection of Howell-Jolly bodies (HJBs) in HIV patients carries significant clinical implications, offering actionable insights into disease progression and guiding therapeutic considerations to optimize patient care and outcomes. As morphological biomarkers of splenic dysfunction and altered erythropoiesis, HJBs provide clinicians with valuable diagnostic clues for identifying individuals at higher risk of developing HIV-related complications and guiding therapeutic interventions.[59] One of the primary clinical implications of detecting HJBs in HIV patients is their utility as prognostic markers for assessing disease severity and predicting clinical outcomes. The presence and abundance of HJBs have been correlated with advanced HIV disease stages, opportunistic infections, and mortality, highlighting their potential as indicators of disease progression and poor prognosis. Integrating HJB assessment into routine hematological evaluations may facilitate risk stratification and early identification of individuals at higher risk of developing complications, prompting timely interventions and personalized therapeutic strategies.

Therapeutic considerations for HIV patients with detectable HJBs encompass a multifaceted approach aimed at addressing underlying erythropoietic abnormalities, splenic dysfunction, and immune dysregulation. Antiretroviral therapy (ART), the cornerstone of HIV management, plays a pivotal role in suppressing viral replication, restoring immune function, and mitigating hematological complications associated with HIV infection. Additionally, adjunctive therapies targeting erythropoiesis, such as erythropoiesis-stimulating agents or iron supplementation, may be considered in individuals with anemia or underlying nutritional deficiencies. Furthermore, strategies aimed at mitigating splenic dysfunction and enhancing erythrocyte clearance may be explored to reduce the burden of HJBs in circulation. Splenectomy, although rarely indicated in the context of HIV, may be considered in select cases of severe splenic dysfunction or refractory hematological complications. Alternatively, therapeutic modalities targeting immune-mediated mechanisms of erythrocyte destruction, such as corticosteroids or immunomodulatory agents, may be beneficial in individuals with autoimmune hemolytic anemia or immune-mediated cytopenias. Regular monitoring of HJB abundance over time may provide clinicians with valuable prognostic

information, guiding treatment adjustments and optimizing clinical outcomes for affected individuals. Serial assessment of HJBs during the course of HIV therapy may serve as a dynamic marker of treatment response, reflecting changes in viral load, CD4+ T-cell counts, and overall disease status. Additionally, longitudinal studies investigating the impact of therapeutic interventions on HJB formation and clinical outcomes are warranted to optimize therapeutic strategies and improve patient care.[60-68]

Conclusion

Howell-Jolly bodies (HJBs) in HIV serve as valuable morphological biomarkers, linking erythropoietic abnormalities to disease progression and offering insights into the complex interplay between hematological dysfunction, immune dysregulation, and viral pathogenesis. The presence and abundance of HJBs in peripheral blood smears provide clinicians with valuable diagnostic clues for assessing disease severity, predicting clinical outcomes, and guiding therapeutic interventions in HIV-infected individuals. The morphological features of HJBs, characterized by small, round, basophilic inclusions within erythrocytes, signify underlying erythropoietic abnormalities and compromised splenic function in HIV. The association between HJBs and disease progression underscores their clinical significance as potential prognostic markers and therapeutic targets, prompting timely interventions and personalized approaches to care for affected individuals.

References

1. Meyer-Myklestad MH, Medhus AW, Lorvik KB, Seljeflot I, Hansen SH, Holm K, Stiksrud B, Trøseid M, Hov JR, Kvale D, Dyrhol-Riise AM. Human immunodeficiency virus–infected immunological nonresponders have colon-restricted gut mucosal immune dysfunction. The Journal of infectious diseases. 2022;225(4):661-674.
2. Henderson DK, Dembry L, Fishman NO, Grady C, Lundstrom T, Palmore TN, Sepkowitz KA, Weber DJ, Society for Healthcare Epidemiology of America. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infection Control & Hospital Epidemiology. 2010;31(3):203-232.
3. d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Lo Caputo S, Arlotti M, Magnani G, Pellizzer G, Maggiolo F. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clinical Infectious Diseases. 2009;49(4):612-622.
4. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (Nijpp). 2023;3(2):64-7.
5. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian J Dental Health Sci [Internet]. 2023 Jun.

Citation: Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology, 2024; 2(5):* 126-137

15 [cited 2024 May 4];3(2):7-14. Available from: http://ajdhs.com/index.php/journal/article/view/39

6. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45
7. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
8. Obeagu EI, Obeagu GU (2024). Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024; 11(2): 9-19.
9. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
10. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
11. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
12. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
13. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
14. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
15. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
16. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
17. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.

Citation: Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology, 2024; 2(5):* 126-137

18. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
19. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
20. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
21. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
22. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
23. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
24. Mehta AB, Hoffbrand AV. Haematology at a Glance. John Wiley & Sons; 2009.
25. Sadelov IO, Bobrynina V, Krasilnikova M, Smetanina N. 1Federal scientific clinical center of pediatric hematology, oncology and immunology named after Dmitriy Rogachev, Moscow, Russian Federation Background: Hemoglobinopathies are heterogeneous group of diseases caused by qualitative (abnormal Hb) or quantitative (thalassemia) failure in. In18TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION STOCKHOLM, SWEDEN JUNE 13-16, 2013 2008; 93(s1):699.
26. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144.

Citation: Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology, 2024; 2(5):* 126-137

https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.

27. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
28. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
29. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
30. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
31. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
32. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
33. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
34. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
35. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-

knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf

36. Lutgendorf SK. Cognitive-behavioral stress management in a symptomatic HIV-1 seropositive population: Effects on mood, coping, immune and neuroendocrine factors. University of Miami; 1994.
37. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
38. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
39. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
40. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
41. Nikolouzakis TK, Falzone L, Lasithiotakis K, Krüger-Krasagakis S, Kalogeraki A, Sifaki M, Spandidos DA, Chrysos E, Tsatsakis A, Tsiaoussis J. Current and future trends in molecular biomarkers for diagnostic, prognostic, and predictive purposes in non-melanoma skin cancer. Journal of Clinical Medicine. 2020;9(9):2868.
42. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
43. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.

Citation: Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology, 2024; 2(5):* 126-137

44. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
45. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
46. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
47. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
48. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
49. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
50. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
51. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
52. Obeagu EI. Erythropoietin in HIV: Bridging the Gap Between Hematology and Virology. Elite Journal of HIV. 2024;2(3):42-54.
53. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024 Jan 12;103(2):e36937.
54. Obeagu EI, Obeagu GU. GATA-1 Regulation of Erythroid Progenitor Cell Differentiation in HIV/AIDS: Molecular Insights and Therapeutic Implications. Elite Journal of Haematology, 2024; 2 (4).:141-59.

Citation: Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology, 2024; 2(5):* 126-137

55. Reddy R. *Study of Hematological Profile in HIV Infected Patients* (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)). 2018.
56. Canny SP, Orozco SL, Thulin NK, Hamerman JA. Immune Mechanisms in Inflammatory Anemia. Annual review of immunology. 2023; 41:405-429.
57. Checconi P, De Angelis M, Marcocci ME, Fraternale A, Magnani M, Palamara AT, Nencioni L. Redox-modulating agents in the treatment of viral infections. International Journal of Molecular Sciences. 2020;21(11):4084.
58. Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and inflammation driven pathophysiology of iron homeostasis—mechanistic insights into anemia of inflammation and its treatment. Nutrients. 2021;13(11):3732.
59. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clinical Infectious Diseases. 2002;35(9):1127-1134.
60. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV. 2024;2(2):60-73.
61. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9):e37354.
62. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.
63. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
64. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
65. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review. 2024;2(1):17-41.
66. Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antiviral research. 2010 Jan 1;85(1):25-33.
67. Channaveerappanavar PB. *Study of Immunological Recovery in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients on Second Line Anti Retroviral Drugs-A Prospective Study* (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India)). 2017.
68. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Quiescence in HIV: Implications for Therapy. Elite Journal of Medicine. 2024;2(4):19-36.

Citation: Obeagu EI. Howell-Jolly Bodies in HIV: Unveiling Morphological Insights into Disease Progression. *Elite Journal of Haematology, 2024; 2(5):* 126-137